Table 1.
Baseline characteristics of the final cohort.
| PC (n = 286) | BPH (n = 104) | p-Value | |
|---|---|---|---|
| Age (years median) | 68 (63–72) | 78 (72–81) | <0.01 |
| Diabetes, n (%) | 44 (15.38) | 28 (26.92) | 0.01 |
| Fasting blood glucose (mg/dL), median (Q1–Q3) | 97 (88–107) | 95 (84–116) | 0.71 |
| Total cholesterol (mg/dL), median (Q1–Q3) | 191.5 (168–221.5) | 175 (150–199) | <0.01 |
| Triglycerides (mg/dL), median (Q1–Q3) | 97 (68–130) | 117 (69–164) | <0.01 |
| PSA (ng/mL), median (Q1–Q3) | 7.8 (5.7–11.6) | 2.05 (0.87–4.32) | <0.01 |
| BCR, n (%) | 56 (19.6) | - |
PC = prostate cancer; BPH = benign prostatic hyperplasia; PSA = prostate-specific antigen; BCR = biochemical recurrence.